fashion -WSS

fashion

author：entertainment 2025-09-30 01:19:46 - browse：89

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Covid isolation guidance eased by the CDC

WSS

Sanofi seeks simpler, safer CRISPR sickle cell cure

How Medicaid coverage policies for immigrants impact new moms

Medicare has a new plan to address drug shortages

Obesity now affects over 1 billion people worldwide, study finds

Cosmetics set for new safety regulation. Why the industry is on board

Clinical trials giant ICON acquires HumanFirst

hotspot

fashion

Wikipedia

New air purifier tech could be key to improving indoor air quality

FDA does about

Guidelines to prevent youth baseball injuries need more muscle

An inside look at PIPEs, biotech's buzzy new financing tool

Peter Hotez and the public health issue of online harassment

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

After affirmative action ruling, medical educators look to 'holistic review'

FogPharma raises $145 million in rare Series E round

George Santos makes 1st court appearance after pleading not guilty to 13 counts

A Q&A with Aletha Maybank, AMA’s chief health equity officer

focus

At Orexo, a ‘turning point’ for everything but digital health

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Cosmetics set for new safety regulation. Why the industry is on board

Startup Neumora takes a novel depression drug to Phase 3

Pfizer highlights cancer drugs it thinks could reignite investor interest

ALS groups 'won't be played again' by the FDA, drug sponsors

entertainment

entertainment

Wikipedia

hotspot